Login to Your Account

ProFibrix Starts Phase III Trial Of FibroCaps in Hemostasis

By Nuala Moran
Staff Writer

Wednesday, June 13, 2012
LONDON – ProFibrix BV has moved swiftly from Phase II development and treated the first patients in the Phase III trial of its hemostasis product FibroCaps, less than four months after meeting with the FDA to discuss how to proceed.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription